ArticleUltrasonography (Seoul, Korea)2020
The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid.
Article in Ultrasonography (Seoul, Korea), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).International journal of surgery (London, England) · 2026Guideline
- Diagnostic Accuracy of Sonazoid-Enhanced Ultrasonography for Detection of Liver Metastasis.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.Gut and liver · 2024Guideline
- Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.Korean journal of radiology · 2024Guideline
- Contrast-enhanced ultrasonography-CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Trial
- Review
- Predictors of tumor conspicuity on Kupffer-phase Sonazoid-enhanced ultrasonography in liver tumors: implications for fusion-guided ablation.Ultrasonography (Seoul, Korea) · 2026Article
- Low-mechanical-index B-mode phase-inversion harmonic imaging significantly improves hepatic lesion conspicuity during Sonazoid Kupffer phase: a prospective comparative study.Ultrasonography (Seoul, Korea) · 2026Article
- Ultrasound-guided ablation of hepatocellular carcinoma: a review of its past, present, and future.Ultrasonography (Seoul, Korea) · 2026Article
- LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid-a single center prospective study.Abdominal radiology (New York) · 2025Article
- Characterization of non-alcoholic fatty liver disease-related hepatocellular carcinoma on contrast-enhanced ultrasound with Sonazoid.Ultrasonography (Seoul, Korea) · 2025Article
- Washout on Contrast-Enhanced Ultrasound of Benign Focal Liver Lesions-A Review on Its Frequency and Possible Causes.Diagnostics (Basel, Switzerland) · 2025Review
- Contrast-enhanced ultrasonography guidance avoids US-CT/MR fusion error for percutaneous radiofrequency ablation of hepatocellular carcinoma.BMC medical imaging · 2024Article
- Diagnostic performance of Sonazoid-enhanced CEUS in identifying definitive hepatocellular carcinoma in cirrhotic patients according to KLCA-NCC 2022 and APASL 2017 guidelines.Insights into imaging · 2024Article
- A non-invasive predictive model based on multimodality ultrasonography images to differentiate malignant from benign focal liver lesions.Scientific reports · 2024Article
- Current status and future perspectives of contrast-enhanced ultrasound diagnosis of breast lesions.Journal of medical ultrasonics (2001) · 2024Review
- A combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound in the Kupffer phase for the diagnosis of well-differentiated hepatocellular carcinoma and atypical focal liver lesions: a prospective, multicenter study.Abdominal radiology (New York) · 2024Article
- Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association.Journal of liver cancer · 2024Article
- Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.Abdominal radiology (New York) · 2024Article
- Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024.Radiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 20 institutions in 5 countries.
Funding
Abstract
The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.